EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination

Karan S Dixit, Priya Kumthekar, Rimas V Lukas, Andrew Williams, Matthew C Tate, James P Chandler, Pouya Jamshidi, Irene Helenowski, Hui Zhang, Orin Bloch, Jeffrey J Raizer

Journal of Neuro-Oncology · 2026

DOI: 10.1007/s11060-026-05446-1 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Karan S Dixit und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA. karan.dixit@northwestern.edu. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Antibodies, Monoclonal. Die Arbeit nennt 26 Literaturangaben. Gefördert von: NIH HHS, AstraZeneca United States, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Survival is poor for patients with recurrent glioblastoma. We prospectively investigated the use of tremelimumab (CTLA-4 inhibitor) and durvalumab (PD-L1 inhibitor) given pre- and post-surgery to assess clinical activity and safety, and to understand the intratumoral immunologic changes. This report focuses on clinical outcomes. METHODS: Recurrent glioblastoma patients were randomized to either: Arm 1, tremelimumab (75 mg every 4 weeks IV); Arm 2, durvalumab (750 mg every 2 weeks); or Arm 3, combination (tremelimumab 75 mg every 4 weeks for 7 doses then every 12 weeks along with durvalumab 750 mg every 2 weeks). Eligible patients received treatment 14 days prior to surgery, then underwent clinically indicated resection, followed by adjuvant treatment starting within 28 days after surgery. RESULTS: Thirty-one patients were evaluable. Median OS and PFS for the entire cohort was 8.9 months (95% CI, 7.5–14.2) and 3.2 months (95% CI, 3.0-4.1), respectively. Median OS for Arm 1 was 7.5 months (95% CI, 2.3–14.7), 13.2 for Arm 2 (95% CI, 2.6–28.0), and 7.9 (95% CI, 4.8–14.2; P = 0.33) for Arm 3. Treatment was well tolerated. One patient developed grade 3 colitis while 2 patients had grade 2 dermatitis. Ten patients had grade 3 hypertension, 4 patients had grade 3 hyperglycemia, and 2 patients had wound complications. There were no treatment related deaths or severe immune related toxicities. CONCLUSION: The combination of tremelimumab and durvalumab is safe in recurrent glioblastoma though there was no statistical improvement in survival. This data aligns with prior studies showing a lack of benefit with checkpoint inhibitors. TRAIL REGISTRATION : ClinicalTrials.Gov Registration NCT02794883. Registration Date 6/9/2016.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaNeoplasm Recurrence, LocalAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansFemaleAntibodies, Monoclonal, HumanizedMaleMiddle AgedAgedAdultFollow-Up StudiesSurvival RateChemotherapy, Adjuvant

Stichwörter der Autor:innen

Checkpoint inhibitorDurvalumabGlioblastomaImmunotherapyTremelimumab

Substanzen

tremelimumabAntibodies, Monoclonal, HumanizeddurvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA. karan.dixit@northwestern.edu.
  • Department of Neurology, Northwestern University, Chicago, IL, USA. karan.dixit@northwestern.edu.
  • Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA.
  • Department of Neurology, Northwestern University, Chicago, IL, USA.
  • Department of Neurosurgery, Northwestern University, Chicago, IL, USA.
  • Department of Pathology, Northwestern University, Chicago, IL, USA.

Förderung

  • NIH HHS
  • AstraZeneca United States
  • National Institutes of Health

Zitieren

APA

Dixit, K. S., Kumthekar, P., Lukas, R. V., Williams, A., Tate, M. C., Chandler, J. P., Jamshidi, P., Helenowski, I., Zhang, H., Bloch, O., & Raizer, J. J. (2026). A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-026-05446-1

Vancouver

Dixit KS, Kumthekar P, Lukas RV, Williams A, Tate MC, Chandler JP, et al. A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-026-05446-1

BibTeX
@article{Dixit2026,
  author = {Dixit, Karan S and Kumthekar, Priya and Lukas, Rimas V and Williams, Andrew and Tate, Matthew C and Chandler, James P and Jamshidi, Pouya and Helenowski, Irene and Zhang, Hui and Bloch, Orin and Raizer, Jeffrey J},
  title = {A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  doi = {10.1007/s11060-026-05446-1}
}
Kostenlos starten →